Sign up to our newsletter

All HyTest SARS-CoV-2 nucleoprotein (NP) antibodies (Cat. #3CV4), including monoclonal antibodies (MAbs) C706, C524, C518, C715, and C527, target the N-terminal part of the nucleoprotein, specifically the region N47-A173. 

We will be attending Medica 2024 in mid-November.

Cardiac troponins I (cTnI) and T (cTnT) are established biomarkers of acute myocardial infarction (AMI). Together with troponin С (TnC), they form a ternary troponin complex (ITC-complex) that represents a significant portion of troponins released into the bloodstream following cardiomyocyte necrosis

In this latest article, the authors further discuss the effects of heparin on the measurement of cardiac isoforms of cTnI and cTnT.

As we celebrate our 30th anniversary, Hytest is proud to offer a special opportunity to our valued customers. Experience the reliability of our tumor markers.This exclusive offer is our way of saying thank you for your continued tr As we celebrate our 30th anniversary, Hytest is proud to offer a special opportunity to our valued customers. Experience the reliability of our tumor markers.This exclusive offer is our way of saying thank you for your continued trust and support. ust and support.

To help find better solutions in tackling tumor cancers investigations, we are very much delighted to announce that our new product, mouse monoclonal antibody (MAb) 1X5cc is launched today!

In collaboration with the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and the European Federation of Laboratory Medicine (EFLM), Hytest has proudly demonstrated its commitment to advancing scientific research in the field of cardiovascular diseases. By sponsoring awards, Hytest has consistently recognized and honoured outstanding work in cardiovascular diagnostics. 

We will be attending the 2024 ADLM Clinical Lab Expo from July 28 to August 1.

By choosing to buy locally, you not only support the North American branch but also ensure a smoother, more cost-effective purchasing experience.

We are excited to announce the launch of a new recombinant Anti-CA-125 antibody RX16 (Cat# 4C29).

May is Cancer Survivor Month. We honor the strength, resilience, and courage of cancer survivors around the world.

We are excited to announce the launch of a new recombinant Glial Fibrillary Acidic Protein (GFAP) antigen, Cat# 8G47.

Hytest is pleased to announce the addition of recombinant monoclonal antibodies RC3A6 and RC8E2 (Cat. # 2I1) to our Insulin product portfolio.

Our monoclonal antibodies (MAbs) can recognize up to 16 different strains of the influenza A virus. 

Meet HyTest team at the China Association of Clinical Laboratory Practice Expo!

Launch of HyTest’s latest monoclonal antibodies targeting the nucleoprotein of influenza B virus!

The Brain Injury Association of America (BIAA) designates March as a month to raise awareness about brain injuries.

We are pleased to inform you that Hytest North America, a subsidiary of Hytest Ltd, will launch local operations in March 2024!

February is American Heart Month, emphasizing the importance of heart health, with a focus on women this year due to their unique risk and often underdiagnosed heart conditions. Current AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guidelines for the Evaluation and Diagnosis of Acute Chest Pain highlight the gender-specific nature of heart disease diagnosis, particularly noting that women generally have lower baseline levels of troponin.

HyTest antibodies should recognize Pirola and Eris variants.